Biosimilars Market Research Reports & Industry Analysis
The worldwide prescription generic drug market has stood the test of time and has endured numerous growing pains. However, it has evolved into a formidable and important participant in the complex world of health care. Generic drugs continue to represent one of the greatest values in healthcare and are of great importance in the area of biopharmaceuticals as well because these products are among the most expensive treatments currently on the market.
Generic drug manufacturers are poised for strong growth in the future because the patent protection for a host of major biopharmaceuticals will expire and new legislative reforms in the generic drug approval process may facilitate bringing products to market. While there are many issues to address, the outlook for the promotion of biosimilars is favorable in the next five years.
Biosimilars Industry Research & Market Reports
-
The 2025-2030 World Outlook for Recombinant Non-Glycosylated Protein Biosimilars
... demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader ... Read More
-
The 2025-2030 World Outlook for Generic Biosimilars
... earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a ... Read More
-
The 2025-2030 World Outlook for Immunology Treatments
... earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a ... Read More
-
The 2025-2030 World Outlook for Erythropoietin Drugs
... earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a ... Read More
-
The 2025-2030 World Outlook for Biosimilars and Follow-on Biologics Drugs
... the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow ... Read More
-
The 2025-2030 World Outlook for Generic Biosimilar Large Molecule Injectables
... the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow ... Read More
-
The 2025-2030 World Outlook for Biobetters - High Efficiency and Economical Costs Foster Adoption
... For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, ... Read More
-
The 2025-2030 World Outlook for Erythropoietins
... for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis ... Read More
-
The 2025-2030 World Outlook for Erythropoietin Stimulating Agents
... potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly ... Read More
-
The 2025-2030 World Outlook for Biosimilars and Follow-on Biologics
... demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader ... Read More
-
The 2025-2030 World Outlook for Biosimilar Monoclonal Antibodies
... potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly ... Read More
-
The 2025-2030 World Outlook for PEGylated Proteins
... earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a ... Read More
-
Biosimilar Market Report by Molecule (Infliximab, Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, Follitropin Alfa, Adalimumab, Pegfilgrastim, Trastuzumab, Bevacizumab, and Others), Indication (Auto-Immune Diseases, Blood Disorders, Diabetes, Oncology, Growth Deficiency, Female Infertility, and Others), Manufacturing Type (In-house Manufacturing, Contract Manufacturing), and Region 2024-2032
... Manufacturing Type (In-house Manufacturing, Contract Manufacturing), and Region 2024-2032 The global biosimilar market size reached US$ 21.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 164.5 Billion by 2032, exhibiting ... Read More
-
Global Biosimilars Market Growth 2024-2030
... forecast to a readjusted size of US$ 18570 million by 2030 with a CAGR of 18.7% during review period. The research report highlights the growth potential of the global Biosimilars market. Biosimilars are expected to ... Read More
-
Global Erythropoietin Drugs Market Size study & Forecast, by Type (Biologics, Biosimilars), by Product (Erythropoietin, Darbepoetin-alfa), by Application (Cancer, Renal Disease, Neurology, Others), and Regional Analysis, 2023-2030
... USD 6.87 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 1.5% during the forecast period 2023-2030. Erythropoietin (EPO), also known as hematopoietin, is a glycoprotein hormone that ... Read More
-
Bevacizumab Biosimilars Global Market Report 2024
... Cervical Cancer; Ovarian Cancer Covering: Cipla Limited; Reliance lifesciences Pvt. Ltd.; Genentech Inc; Fujifilm Kyowa Kirin Biologics Co. Ltd.; Pfizer Inc. Bevacizumab Biosimilars Global Market Report 2024 from The Business Research Company provides strategists, marketers ... Read More
-
Biosimilar Therapeutic Peptides Global Market Report 2024
... Disorders; Dermatology; Respiratory Disorders Covering: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Novartis AG; Sanofi SA Biosimilar Therapeutic Peptides Global Market Report 2024 from The Business Research Company provides strategists, marketers and ... Read More
-
Trastuzumab Biosimilars Global Market Report 2024
... Outlook Therapeutics lnc.; Merck & Co.; Amgen Inc.; BioXpress Therapeutics SA Trastuzumab Biosimilars Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to ... Read More
-
Oral Biologics & Biosimilars Global Market Report 2024
... Disease 3) By Molecule Type: Vaccines; Proteins and Peptides; Monoclonal Antibodies Molecule Types 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies Covering: Merck & Co. Inc.; GlaxoSmithKline; Novo Nordisk; ALK-Abelló; Aimmune Therapeutics Inc. ... Read More
-
Rituximab Biosimilars Global Market Report 2024
... Order Covering: Teva/Cellitron; Novartis AG; Pfizer; BIOCAD; Shanghai Henlius Biotech Inc. Rituximab Biosimilars Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to ... Read More
-
Pegfilgrastim Biosimilars Global Market Report 2024
... Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market. This report focuses on pegfilgrastim biosimilars market which is experiencing ... Read More
-
Filgrastim Biosimilars Global Market Report 2024
... Pharmacy; Retail Pharmacy; Online Pharmacy Covering: Teva Pharmaceutical Industries Ltd; Novartis International AG; Biocon Limited; Intas Biopharmaceuticals; Dr. Reddy's Laboratories Filgrastim Biosimilars Global Market Report 2024 from The Business Research Company provides strategists, marketers and ... Read More
-
Biosimilars Global Market Report 2024
... Deficiency; Infectious Diseases Covering: Amgen; Pfizer; Novartis AG; Samsung Bioepis Co., Ltd.; Viatris Biosimilars Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need ... Read More
-
Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2024
... Rheumatoid Arthritis; Ulcerative Colitis; Ankylosing Spondylitis; Plaque Psoriasis Covering: Biogen; Novartis (Sandoz); Pfizer; Amgen; Celltrion Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management ... Read More
-
Global Biosimilars - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029
... billion by 2029, growing at a CAGR of 18.32% during the forecast period (2024-2029). The impact of COVID-19 on the biosimilars market may be significant, and it has imposed a great challenge on the pharmaceutical ... Read More
Research Assistance
